Treatment patterns of anti-TNF agents in Italy: An observational study;Pattern di trattamento con farmaci anti-TNF in Italia: Uno studio osservazionale

Reumatismo

Volumn 63, Issue 1, 2011, Pages 18-28

  Punzi, L ^a   Matucci Cerinic, M ^b   Cantini, F ^c   Bagnato, G ^d   Fiocco, U ^a   Ferri, C ^e   Bombardieri, S ^f  

^a UNIVERSITY OF PADOVA   (Italy)

^b Geriatric Department   (Italy)

^c MISERICORDIA E DOLCE HOSPITAL   (Italy)

^d UNIVERSITY OF MESSINA   (Italy)

^e UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^f UNIVERSITY OF PISA   (Italy)

Author keywords

Anti TNF; Rheumatoid arthritis; Treatment patterns

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB;

ADULT; ARTICLE; DOSE RESPONSE; DRUG COST; DRUG DOSE ESCALATION; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG UTILIZATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFUSIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; ITALY; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MOTIVATION; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79955497650     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002; 46: 328-346.
2. Luqmani R, Hennell S, Estrach C, Birrell F, Bosworth A, Davenport G, et al; British Society for Rheumatology; British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group. British Society for Rheumatology and British health professionals in Rheumatology guideline for the management of rheumatoid arthritis (the first two years). Rheumatology (Oxford) 2006; 45: 1167-1169.
3. Donahue KE, Gartlehner G, Jonas DE, Lux LJ, Thieda P, Jonas BL, et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 2008; 148: 124-134.
4. Bennett AN, Peterson P, Zain A, Grumley J, Panayi G, Kirkham B. Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure. Rheumatology (Oxford) 2005; 44: 1026-1031.
5. Feltelius N, Fored CM, Blomqvist P, Bertils-son L, Geborek P, Jacobsson LT, Lindblad S, et al; ARTIS Group. Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept. Ann Rheum Dis 2005; 64: 246-252.
6. Hyrich KL, Symmons DP, Watson KD, Sil-man AJ; British Society for Rheumatology Bi-ologics Register. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54: 1786-1794.
7. Finckh A, Simard JF, Gabay C, Guerne PA; SCQM physicians. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis 2006; 65: 746-752.
8. Strangfeld A, Hierse F, Kekow J, von Hinue-ber U, Tony HP, Dockhorn R, et al. Comparative effectiveness of TNFalpha inhibitors in combination with either methotrexate or leflu-nomide. Ann Rheum Dis 2009; 68: 1856-1862.
9. Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006; 10: iii-iv, xi-xiii, 1-229.
10. van Riel PL, Taggart AJ, Sany J, Gaubitz M, Nab HW, Pedersen R, et al; Add Enbrel or Replace Methotrexate Study Investigators. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study. Ann Rheum Dis 2006; 65: 1478-1483.
11. Rubbert-Roth A, Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther. 2009; 11 (Suppl. 1): S1.
12. van Vollenhoven R, Harju A, Brannemark S, Klareskog L. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. Ann Rheum Dis 2003; 62: 1195-1198.
13. Nikas SN, Voulgari PV, Alamanos Y, Papado-poulos CG, Venetsanopoulou AI, Georgiadis AN, et al. Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study. Ann Rheum Dis 2006; 65: 257-260.
14. Ariza-Ariza R, Navarro-Sarabia F, Hernán-dez-Cruz B, Rodríguez-Arboleya L, Navarro-Compán V, Toyos J. Dose escalation of the anti-TNF-alpha agents in patients with rheumatoid arthritis. A systematic review. Rheumatology (Oxford) 2007; 46: 529-532.
15. Brocq O, Roux CH, Albert C, Breuil V, Aknouche N, Ruitord S, et al. TNFalpha antagonist continuation rates in 442 patients with inflammatory joint disease. Joint Bone Spine 2007; 74: 148-154.
16. Duclos M, Gossec L, Ruyssen-Witrand A, Salliot C, Luc M, Guignard S, et al. Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients. J Rheuma-tol 2006; 33: 2433-2438.
17. Favalli EG, Marchesoni A, Colombo GL, Sin-igaglia L. Pattern of use, economic burden and vial optimization of infliximab for rheumatoid arthritis in Italy. Clin Exp Rheumatol 2008; 26: 45-51.
18. Caporali R, Sarzi-Puttini P, Atzeni F, Gorla R, Filippini M, Marchesoni A, et al. Switching TNF-alpha antagonists in rheumatoid arthritis: The experience of the LORHEN registry. Autoimmun Rev 2010; 9: 465-469.
19. Marchesoni A, Zaccara E, Gorla R, Bazzani C, Sarzi-Puttini P, Atzeni F, et al. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci 2009; 1173: 837-846.
20. NICE (2007).National Institute for Health and Clinical Excellence (NICE) technology appraisal guidance 130 (TA130). Adalimum-ab, etanercept and infliximab for the treatment of rheumatoid arthritis. Includes a review of technology appraisal guidance 36. Issue date: October 2007. Available at: http://www.nice.org.uk/nicemedia/pdf/TA130guidance.pdf.
21. Gomez-Reino JJ, Carmona L; BIOBADASER Group. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 2006; 8: R29.
22. Kvalvik AG, Lefsaker L, Dyvik S, Brun JG. Anti-tumor necrosis factor-alpha therapy in the ordinary clinical setting: Three-year effectiveness in patients with rheumatoid arthritis. Joint Bone Spine 2007; 74: 606-611.
23. Genta MS, Kardes H, Gabay C. Clinical evaluation of a cohort of patients with rheumatoid arthritis treated with anti-TNF-alpha in the community. Joint Bone Spine 2006; 73: 51-56.
24. Du Pan SM, Dehler S, Ciurea A, et al; on behalf of the Swiss Clinical Quality Management Physicians. Comparison of Drug Retention Rates and Causes of Drug Discontinuation Between Anti-Tumor Necrosis Factor Agents in Rheumatoid Arthritis. Arthritis & Rheumatism. Arthritis Care Res 2009; 61: 560-568.
25. Durez P, Van den Bosch F, Corluy L, Veys EM, De Clerck L, Peretz A, et al. A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study. Rheumatology (Oxford) 2005; 44: 465-468.
26. Buch MH, Bingham SJ, Bejarano V, Bryer D, White J, Reece R, et al. Therapy of patients with rheumatoid arthritis: outcome of inflix-imab failures switched to etanercept. Arthritis Rheum 2007; 57: 448-453.
27. Iannone F, Trotta F, Montecucco C, Giacome-lli R, Galeazzi M, Matucci-Cerinic M, Ferri C, et al; GISEA (Gruppo Italiano per lo Studio delle Early Arthritis). Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discon- tinued infliximab because of side effects. Ann Rheum Dis 2007; 66: 249-252.
28. Bombardieri S, Ruiz AA, Fardellone P, Geu-sens P, McKenna F, Unnebrink K, et al; Research in Active Rheumatoid Arthritis (ReAct) Study Group. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology (Oxford) 2007; 46: 1191-1199.
29. Walsh CA, Minnock P, Slattery C, Kennedy N, Pang F, Veale DJ, et al. Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis. Rheumatology (Oxford) 2007; 46: 1148-1152.
30. Smolen JS, Landewé R, Breedveld FC, Dou-gados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheu-matic drugs. Ann Rheum Dis 2010; 69: 964-975.
31. Russell A, Beresniak A, Bessette L, Haraoui B, Rahman P, Thorne C, et al. Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis. Clin Rheumatol 2009; 28: 403-412.
32. Vera-Llonch M, Massarotti E, Wolfe F, Shad-ick N, Westhovens R, Sofrygin O, et al. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-alpha antagonists. J Rheumatol 2008; 35: 1745-1753.
33. Yuan Y, Trivedi D, Maclean R, Rosenblatt L. Indirect cost-effectiveness analyses of abata-cept and rituximab in patients with moderate-to-severe rheumatoid arthritis in the United States. J Med Econ 2010; 13: 33-41.